Dr. Joseph Richard Nies, DC Chiropractor Medicare: May Accept Medicare Assignments Practice Location: 118 Gould Rd, Newfoundland, NJ 07435 Phone: 973-697-6399 Fax: 973-697-6399 |
Dr. Jennie Ann Lippiello, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 2920 Route 23 South, Newfoundland, NJ 07435 Phone: 973-208-0303 Fax: 973-208-2262 |
Dr. Robert J Natusch Jr., DC CHIROPRACTOR Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 2713 Rt 23 So, Newfoundland, NJ 07435 Phone: 973-697-7000 |
Lakeland Chiropractic Center Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 2969 Route 23, Newfoundland, NJ 07435 Phone: 973-697-2455 Fax: 973-697-0800 |
Dr. Kenneth D Vindeni, DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 7 Oak Ridge Rd Apt 3, Newfoundland, NJ 07435 Phone: 973-697-2455 Fax: 973-697-0800 |
News Archive
New software, which will allow GP practice managers to improve healthcare for chronic illnesses including strokes, Alzheimer's and cancer, will be unveiled by scientists from The University of Manchester next week (13 & 14 March).
Rodents, medicines and drug developments are all on the agenda during a new series of public lectures being staged by the University of Greenwich's Faculty of Engineering & Science.
The human genetic disease dyskeratosis congenita (DKC) is an autosomal dominant disease that leads to abnormalities in tissues with a rapid cell turnover - the skin, nails, bone marrow, lungs and gut. Patients with DKC experience life-threatening symptoms. Bone marrow failure increases their risk of fatal infections and cancer. Many die before the age of 30 and management of the disease is limited to trying to treat its symptoms.
Blocking a factor that can activate the human immune response against intestinal bacteria or certain foods could prevent the development of celiac disease in those most at risk, researchers report in the journal Nature.
Allergan plc, a leading global pharmaceutical company, and KYTHERA Biopharmaceuticals, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market, today announced that they have entered into a definitive agreement under which Allergan has agreed to acquire KYTHERA in a cash and equity transaction valued at $75 per KYTHERA share, or approximately $2.1 billion.
› Verified 5 days ago